NCT00971425View on ClinicalTrials.gov

Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)

PHASE3CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

September 8, 2009

Primary Completion Date

November 16, 2009

Study Completion Date

October 8, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

Pandemrix (GSK investigational influenza GSK2340272A vaccine)

2 doses intramuscular injections

BIOLOGICAL

Fluarix™

1 dose intramuscular injection

BIOLOGICAL

Placebo

1 dose intramuscular injection

Trial Locations (6)

12157

GSK Investigational Site, Berlin

22335

GSK Investigational Site, Hamburg

22415

GSK Investigational Site, Hamburg

55116

GSK Investigational Site, Mainz

91126

GSK Investigational Site, Rednitzhembach

01705

GSK Investigational Site, Freital

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) | Biotech Hunter | Biotech Hunter